[go: up one dir, main page]

PL4013751T3 - Pochodne 2-hydroksycykloalkano-1-karbamoilu - Google Patents

Pochodne 2-hydroksycykloalkano-1-karbamoilu

Info

Publication number
PL4013751T3
PL4013751T3 PL20767476.3T PL20767476T PL4013751T3 PL 4013751 T3 PL4013751 T3 PL 4013751T3 PL 20767476 T PL20767476 T PL 20767476T PL 4013751 T3 PL4013751 T3 PL 4013751T3
Authority
PL
Poland
Prior art keywords
hydroxycycloalkane
carbamoyl derivatives
carbamoyl
derivatives
Prior art date
Application number
PL20767476.3T
Other languages
English (en)
Inventor
Martin Bolli
John Gatfield
Corinna Grisostomi
Lubos Remen
Christoph SAGER
Cornelia Zumbrunn
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of PL4013751T3 publication Critical patent/PL4013751T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12Triazine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL20767476.3T 2019-08-15 2020-08-14 Pochodne 2-hydroksycykloalkano-1-karbamoilu PL4013751T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2019071921 2019-08-15
PCT/EP2020/072865 WO2021028570A1 (en) 2019-08-15 2020-08-14 2-hydroxycycloalkane-1-carbamoyl derivatives

Publications (1)

Publication Number Publication Date
PL4013751T3 true PL4013751T3 (pl) 2025-05-19

Family

ID=72355943

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20767476.3T PL4013751T3 (pl) 2019-08-15 2020-08-14 Pochodne 2-hydroksycykloalkano-1-karbamoilu

Country Status (20)

Country Link
US (1) US12291519B2 (pl)
EP (1) EP4013751B1 (pl)
JP (1) JP7604457B2 (pl)
KR (1) KR102832308B1 (pl)
CN (1) CN114269737A (pl)
AU (1) AU2020329609B2 (pl)
BR (1) BR112021026829A2 (pl)
CA (1) CA3147454A1 (pl)
ES (1) ES3015725T3 (pl)
HR (1) HRP20250372T1 (pl)
HU (1) HUE070924T2 (pl)
IL (1) IL289197B1 (pl)
MA (1) MA56883B1 (pl)
MX (1) MX2022001789A (pl)
PH (1) PH12022550338A1 (pl)
PL (1) PL4013751T3 (pl)
RS (1) RS66695B1 (pl)
TW (1) TWI864071B (pl)
UA (1) UA128909C2 (pl)
WO (1) WO2021028570A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12404295B2 (en) 2019-08-09 2025-09-02 Idorsia Pharmaceuticals Ltd (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives
JP7612663B2 (ja) 2019-08-09 2025-01-14 イドルシア・ファーマシューティカルズ・リミテッド (2-アセタミジル)チオ-ベータ-d-ガラクトピラノシド誘導体
AU2020338816A1 (en) 2019-08-29 2022-04-14 Idorsia Pharmaceuticals Ltd Alpha-D-galactopyranoside derivatives
CN115244045A (zh) * 2019-12-24 2022-10-25 糖模拟物有限公司 抑制半乳凝素-3的c-糖苷酮、醚和醇
EP4225752B1 (en) 2020-10-06 2024-12-11 Idorsia Pharmaceuticals Ltd Spiro derivatives of alpha-d-galactopyranosides
EP4237419A1 (en) 2020-11-02 2023-09-06 Idorsia Pharmaceuticals Ltd Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives
IL304923A (en) * 2021-02-09 2023-10-01 Idorsia Pharmaceuticals Ltd History of hydroxyheterocycloalkane-carbamoyl
ES3033422T3 (en) 2021-03-03 2025-08-04 Idorsia Pharmaceuticals Ltd Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives
WO2022189459A2 (en) * 2021-03-10 2022-09-15 Galecto Biotech Ab Novel galactoside inhibitor of galectins
JP2024517936A (ja) * 2021-05-14 2024-04-23 グリコミメティクス, インコーポレイテッド ガレクチン-3阻害性c-グリコシド
US20240287121A1 (en) * 2021-05-28 2024-08-29 Glycomimetics, Inc. Galectin-3 inhibiting c-glycoside oximes

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100172D0 (sv) 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
SE0401301D0 (sv) * 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
JP6055928B2 (ja) 2012-10-10 2016-12-27 ガレクティン・セラピューティクス・インコーポレイテッドGalectin Therapeutics, Inc. 糖尿病性腎症および関連障害の処置のためのガラクトース分枝炭水化物化合物
EP2914269B1 (en) 2012-10-31 2020-07-29 Galecto Biotech AB Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis
JP6366598B2 (ja) * 2012-11-15 2018-08-01 タフツ ユニバーシティー ガレクチンタンパク質阻害剤を用いて被験体の眼の血管新生または繊維症を処置し、調節し、または、予防する方法、組成物、およびキット
WO2016120403A1 (en) * 2015-01-30 2016-08-04 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
CN109879859B (zh) 2015-07-06 2022-01-25 吉利德科学公司 Cot调节剂及其使用方法
US10889610B2 (en) 2016-07-12 2021-01-12 Galecto Biotech Ab Alpha-D-galactoside inhibitors of galectins
AU2018265813A1 (en) 2017-05-12 2019-12-05 Galectin Sciences, Llc Compounds for the treatment of systemic insulin resistance disorders and the use thereof
CA3062648A1 (en) 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the prevention and treatment of diseases and the use thereof
US11267811B2 (en) * 2017-09-27 2022-03-08 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
US11072626B2 (en) 2017-10-11 2021-07-27 Bristol-Myers Squibb Company Small molecule inhibitors of Galectin-3
AU2018361991A1 (en) 2017-10-31 2020-05-14 Galectin Sciences, Llc Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof
WO2020078808A1 (en) 2018-10-15 2020-04-23 Galecto Biotech Ab Galactoside inhibitor of galectins
WO2020078807A1 (en) 2018-10-15 2020-04-23 Galecto Biotech Ab Prodrug of galactoside inhibitors of galectins
CN113412267B (zh) 2018-11-21 2025-06-27 格莱克特生物技术公司 半乳糖凝集素的α-D-半乳糖苷抑制剂
JP7577682B2 (ja) 2019-04-10 2024-11-05 ブリストル-マイヤーズ スクイブ カンパニー ガレクチン-3の低分子阻害剤
CN114555620A (zh) 2019-07-03 2022-05-27 格莱克特生物技术公司 半乳糖凝集素的新型半乳糖苷抑制剂
CN114450282A (zh) 2019-07-05 2022-05-06 格莱克特生物技术公司 半乳糖凝集素的新型半乳糖苷抑制剂
JP7612663B2 (ja) 2019-08-09 2025-01-14 イドルシア・ファーマシューティカルズ・リミテッド (2-アセタミジル)チオ-ベータ-d-ガラクトピラノシド誘導体
US12404295B2 (en) 2019-08-09 2025-09-02 Idorsia Pharmaceuticals Ltd (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives
AU2020338816A1 (en) 2019-08-29 2022-04-14 Idorsia Pharmaceuticals Ltd Alpha-D-galactopyranoside derivatives
EP4225752B1 (en) 2020-10-06 2024-12-11 Idorsia Pharmaceuticals Ltd Spiro derivatives of alpha-d-galactopyranosides
EP4237419A1 (en) 2020-11-02 2023-09-06 Idorsia Pharmaceuticals Ltd Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives
IL304923A (en) 2021-02-09 2023-10-01 Idorsia Pharmaceuticals Ltd History of hydroxyheterocycloalkane-carbamoyl
ES3033422T3 (en) 2021-03-03 2025-08-04 Idorsia Pharmaceuticals Ltd Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives

Also Published As

Publication number Publication date
UA128909C2 (uk) 2024-11-20
AU2020329609B2 (en) 2025-10-02
EP4013751B1 (en) 2025-01-22
EP4013751A1 (en) 2022-06-22
MA56883B1 (fr) 2025-04-30
PH12022550338A1 (en) 2023-02-06
JP2022544248A (ja) 2022-10-17
HRP20250372T1 (hr) 2025-06-06
AU2020329609A1 (en) 2022-02-24
CN114269737A (zh) 2022-04-01
IL289197B1 (en) 2025-10-01
HUE070924T2 (hu) 2025-07-28
JP7604457B2 (ja) 2024-12-23
IL289197A (en) 2022-02-01
KR20220047585A (ko) 2022-04-18
EP4013751C0 (en) 2025-01-22
WO2021028570A1 (en) 2021-02-18
TW202115039A (zh) 2021-04-16
MX2022001789A (es) 2022-03-11
KR102832308B1 (ko) 2025-07-10
US20220324847A1 (en) 2022-10-13
US12291519B2 (en) 2025-05-06
BR112021026829A2 (pt) 2022-02-22
TWI864071B (zh) 2024-12-01
CA3147454A1 (en) 2021-02-18
RS66695B1 (sr) 2025-05-30
ES3015725T3 (en) 2025-05-07

Similar Documents

Publication Publication Date Title
PT3958977T (pt) Derivados de camptotecina
EP3994692C0 (en) BINARY COMPUTING CELL IN MEMORY
IL292161A (en) New methylquinazolinone derivatives
EP3833739A4 (en) STRAIN OF AKKERMANSIA MUCINIPHILA
EP4013751C0 (en) 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES
LT3830085T (lt) Deuterinti lanifibranoro dariniai
EP4077334C0 (en) FUROINDAZOLE DERIVATIVES
DK3768669T3 (da) Piperazinazaspiroderivater
EP4021904C0 (en) ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES
EP3919491C0 (en) AKT INHIBITOR
EP3967649C0 (en) LIPID NANOPARTICLE
DK3823970T3 (da) Yderligere substituerede triazoloquinoxalinderivater
EP3742771C0 (en) M2M SM-SR TO SM-DP NOTIFICATION
DK3823971T3 (da) Substituerede triazol-quinoxalin-derivater
EP4034170A4 (en) TGF-BETA RELATED POLYPEPTIDES
DK3796975T3 (da) Sulfonylaminobenzamidderivater
EP3973348A4 (en) HEAD MOUNT DISPLAYS
EP3957391C0 (en) AGITATOR
EP4082837A4 (en) Roof box
EP3975220A4 (en) Display panel
EP3965638C0 (en) VAGINAL SPECULUM
EP3962498A4 (en) Combination therapies
DK3894410T3 (da) Substituerede xanthinderivater
DK3738452T3 (da) Fordamper
DK3770162T3 (da) Dihydrochromenderivater